Efor Expands Its Asian Footprint Through Acquisition of No Deviation

Efor Expands Its Asian Presence via Acquisition of No Deviation

Efor, a global leader in quality and regulatory compliance for the Life Sciences industry, has taken a significant step in its strategic expansion within Asia by acquiring No Deviation, a Singapore-based firm renowned for its expertise in Commissioning, Qualification, and Validation (CQV), Computer System Validation (CSV), Quality Compliance, and Digital Enablement. This acquisition, announced on March 3, 2026, marks a pivotal moment in Efor's journey as it fortifies its resources and reach in a rapidly evolving market.

Founded in 2013, Efor has established an international platform that emphasizes quality and compliance tailored specifically for the Life Sciences sector. With a robust workforce of over 3,000 professionals across 18 countries, Efor has partnered with leading entities in pharmaceuticals, biotechnology, and medical devices. The company's expansion into Asia has been a calculated move, and this latest acquisition is a testament to its commitment to embedding itself further into the local industry.

No Deviation, which began its operations in 2007, has successfully carved out a niche for itself in Singapore, China, and Ireland, with Singapore functioning as its primary operational hub. With a reputation for delivering strong local execution capabilities, particularly in the fast-growing biopharmaceutical landscapes, No Deviation's incorporation into Efor is projected to elevate both organizations. This merger not only enhances Efor's capacities in CQV but also amplifies its high-level regulatory compliance services in the region.

The cooperation between Efor and No Deviation is grounded in a shared vision of delivering high-value quality and compliance solutions for complex industrial projects. According to Mathieu Roger, the founder and president of Efor,